Printer Friendly

SURVIVAL TECHNOLOGY AND LOTUS BIOCHEMICAL ANNOUNCE AGREEMENT FOR EIGHT NEW AUTO-INJECTOR PRODUCTS

 ROCKVILLE, Md., Nov. 16 /PRNewswire/ -- James H. Miller, president and chief executive officer of Survival Technology, Inc. (STI) (NASDAQ-NMS: STIQ) and R.J. Kirk, board chairman of Lotus Biochemical Corporation, today announced the signing of a licensing agreement in which STI will develop and manufacture new products in eight therapeutic categories, all using a variety of STI's patented auto-injector delivery systems.
 "This alliance will have far-reaching impact in the growing home health care market because of the unique cost-savings and quality-of- life benefits these innovative products offer," Miller said. The STI auto-injector is a pen-like device that allows patients to self- administer precise, metered doses of injectable medication quickly, safely, easily and without ever seeing the needle.
 Products covered in the agreement include auto-injectors containing two combination vaccines, an anti-emetic, a glucocorticoid, a non- narcotic analgesic, an anti-convulsant as well as drugs to treat male impotence and panic disorder. According to industry estimates, U.S. sales of products in these therapeutic categories totaled more than $2.6 billion in 1992.
 STI plans to submit New Drug Applications (NDAs), funded by Lotus, to the Food and Drug Administration (FDA) for some of the new products by 1995. Plans are underway for Lotus to begin marketing some of these products in the United States by late 1995, pending FDA approvals.
 The 10-year agreement, with renewal options, grants worldwide marketing rights to Lotus for these products based on STI's auto- injector technology.
 On Aug. 3, STI and Lotus announced a similar licensing agreement for the supply and marketing of a morphine-filled auto-injector product for home health care pain management. STI's NDA for this product has been approved by FDA, and the product will be introduced by Lotus in early 1994.
 STI is a technology-based health care company that designs, develops and produces automatic injectors and pre-filled syringes with major focus on safe and convenient participation by the patient in injection therapy. The company also supplies delivery system design, pharmaceutical research and development, and sterile product manufacturing to pharmaceutical companies worldwide.
 Lotus Biochemical markets proprietary ethical pharmaceutical products under its own label and on behalf of major pharmaceutical companies. Lotus is an affiliate of General Injectables and Vaccines, the largest independent marketer and distributor of pharmaceutical products to physician offices in the United States.
 -0- 11/16/93
 /CONTACT: Frank Massino of Survival Technology, 301-926-1800, or Iain Speirs of Lotus Biochemical, 703-731-3344/
 (STIQ)


CO: Survival Technology, Inc.; Lotus Biochemical Corporation ST: Maryland IN: MTC SU: PDT

IH-PB -- DC005 -- 4949 11/16/93 09:48 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1993
Words:421
Previous Article:JHM MORTGAGE SECURITIES L.P. ANNOUNCES THIRD QUARTER RESULTS AND PROGRESS ON PLAN TO CONVERT TO CORPORATION
Next Article:CHINA ORDERS SIX AIRBUS A340s
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters